Wall Street Zen Downgrades Avanos Medical (NYSE:AVNS) to Buy

Avanos Medical (NYSE:AVNS) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

AVNS has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

Avanos Medical Trading Down 2.6%

Shares of NYSE AVNS opened at $14.12 on Friday. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $15.68. The company has a 50-day moving average of $13.05 and a two-hundred day moving average of $12.12. The company has a market cap of $656.44 million, a PE ratio of -8.93 and a beta of 1.07. The company has a current ratio of 2.15, a quick ratio of 1.26 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The firm’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.43 earnings per share. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, equities analysts expect that Avanos Medical will post 1.32 earnings per share for the current fiscal year.

Institutional Trading of Avanos Medical

A number of institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Avanos Medical by 1,596,514.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock worth $167,287,000 after buying an additional 14,895,480 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Avanos Medical by 28.0% in the fourth quarter. Armistice Capital LLC now owns 3,200,000 shares of the company’s stock valued at $35,936,000 after purchasing an additional 700,000 shares during the last quarter. State Street Corp raised its holdings in shares of Avanos Medical by 2.8% in the fourth quarter. State Street Corp now owns 1,954,785 shares of the company’s stock valued at $21,952,000 after purchasing an additional 53,523 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Avanos Medical by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company’s stock worth $12,180,000 after purchasing an additional 16,980 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Avanos Medical by 20.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company’s stock valued at $11,687,000 after purchasing an additional 176,716 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.